Skip to main content

Table 1 HBV patient characteristics and outcome of evaluation

From: Re-evaluation of chronic hepatitis B and hepatitis C patients lost to follow-up: results of the Northern Holland hepatitis retrieval project

  N = 50 (100%)
Sex
 Male 22 (44%)
 Female 28 (56%)
Age (years) (mean ± SD) 48 ± 9.7
Migrational background
 Dutch / WE 4 (8%)
 EE/EA 12 (24%)
 NA 2 (4%)
 SSA 7 (14%)
 SEA 23 (46%)
 LA 2 (4%)
ALT (U/l) (mean + SD) combined with HBV DNA levels (IU/mL)
 Normal (0-34 U/l) and HBV DNA < 2.0 · 104 44 (88%)
 ALT >1xULN and HBV DNA < 2.0 · 104 3 (6%)
 ALT >1xULN and HBV DNA > 2,0 · 104 3 (6%)
Fibrosis stage
 Unknown 2 (4%)
 F0-F1 45 (90%)
 F2-F3 3 (6%)
Management advice
 No Follow-up needed 3 (6%)
 ALT levels every 6-12 months 25 (50%)
 ALT levels and HCC screening every 6-12 months 14 (28%)
 Strict follow-up every 3-6 months 5 (10%)
 Antiviral therapy 3 (6%)
  1. WE Western Europe, EE Eastern Europe, EA EuroAsia, NA North Africa, SSA Sub-Saharan Africa, SEA South East Asia, LA Latin America, ALT Alanine-aminotransferase, ULN Upper limit of normal, HCC Hepatocellular carcinoma